Frontlight ResearchEarly access
Taking peoplePhase 1
AZD4063 for adults with dilated cardiomyopathy caused by a PLN R14del gene change
Tests AZD4063 for safety in adults with PLN R14del dilated cardiomyopathy.
Key facts
- Who runs it
- AstraZeneca AB
- Where
- Netherlands4 sites in 1 countryChoose a country to see its sites
- Trial code
- Registry title
- A trial to learn how safe AZD4063 is, how it moves throughout the body over time, and how it affects the levels of PLN mRNA in adults with dilated cardiomyopathy because of an R14del mutation in the PLN gene
- Status
- Recruiting
- Phase
- Phase 1
- People taking part
- 23 people, planned
- Started
- 20 Nov 2025
- Expected to end
- 29 Oct 2027
- Type of study
- Interventional
- Record updated
- 20 July 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with dilated cardiomyopathy caused by an R14del mutation in the PLN gene. Dilated cardiomyopathy is a weakened, enlarged heart muscle. The trial tests the safety of AZD4063 and how it moves through the body.
- Age
- 18 Years and older
- Sex
- All sexes can join.
- Disease stage
- Dilated cardiomyopathy caused by the PLN R14del gene change.
- Biomarker or test result
- An R14del mutation in the PLN gene.
Main reasons for not taking part
- Healthy volunteers cannot join.
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Plain-language title
- AZD4063 for adults with dilated cardiomyopathy caused by a PLN R14del gene changeGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Record updated
- 20 July 2026